JP2005533007A - Ｌｘｒ調節因子を用いる治療方法 - Google Patents

Ｌｘｒ調節因子を用いる治療方法 Download PDF

Info

Publication number
JP2005533007A
JP2005533007A JP2003579741A JP2003579741A JP2005533007A JP 2005533007 A JP2005533007 A JP 2005533007A JP 2003579741 A JP2003579741 A JP 2003579741A JP 2003579741 A JP2003579741 A JP 2003579741A JP 2005533007 A JP2005533007 A JP 2005533007A
Authority
JP
Japan
Prior art keywords
alkyl
het
cycloalkyl
unsubstituted
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2003579741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533007A5 (enExample
Inventor
ウィリアム・ジェイ・ケアンズ
エレイン・エイ・アービング
アンドリュー・エイ・パーソンズ
ピーター・イー・ソーデン
ジル・シー・リチャードソン
スティーブン・エイ・バービッジ
メアリー・ビンソン
マイク・エイ・ワトソン
カール・ホイットニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JP2005533007A publication Critical patent/JP2005533007A/ja
Publication of JP2005533007A5 publication Critical patent/JP2005533007A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Control Of El Displays (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003579741A 2002-03-27 2003-03-26 Ｌｘｒ調節因子を用いる治療方法 Ceased JP2005533007A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36842402P 2002-03-27 2002-03-27
PCT/US2003/009225 WO2003082198A2 (en) 2002-03-27 2003-03-26 Methods of treatment with lxr modulators

Publications (2)

Publication Number Publication Date
JP2005533007A true JP2005533007A (ja) 2005-11-04
JP2005533007A5 JP2005533007A5 (enExample) 2006-06-08

Family

ID=28675488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579741A Ceased JP2005533007A (ja) 2002-03-27 2003-03-26 Ｌｘｒ調節因子を用いる治療方法

Country Status (5)

Country Link
US (1) US20050171084A1 (enExample)
EP (1) EP1511483A4 (enExample)
JP (1) JP2005533007A (enExample)
AU (1) AU2003220521A1 (enExample)
WO (1) WO2003082198A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005521705A (ja) * 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 化合物および方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1497270A4 (en) * 2002-03-27 2006-01-04 Smithkline Beecham Corp AMID COMPOUNDS AND METHOD FOR THEIR USE
JP2005521721A (ja) * 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 酸およびエステル化合物ならびにその使用方法
AU2003226094A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
WO2004113533A1 (ja) * 2003-06-24 2004-12-29 Sumitomo Chemical Company, Limited 肝臓Ｘ受容体αスプライシング変異体タンパク質、その遺伝子及びそれらの利用
US7390835B2 (en) * 2003-10-30 2008-06-24 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
JP2007516258A (ja) * 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
US20060069076A1 (en) * 2004-07-01 2006-03-30 Yu Sun LXR/RXR-related methods and compositions
AU2006272922A1 (en) 2005-07-22 2007-02-01 Amgen Inc. Aniline sulfonamide derivatives and their uses
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
US8497122B2 (en) 2008-04-11 2013-07-30 Washington University Biomarkers for Niemann-pick C disease and related disorders
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
AU2015204572B2 (en) * 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
KR101947976B1 (ko) 2015-12-15 2019-02-13 아스트라제네카 아베 이소인돌 화합물
EP3638661A1 (en) 2017-06-14 2020-04-22 Astrazeneca AB 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
US20200038410A1 (en) * 2018-07-26 2020-02-06 Loyola University Chicago Methods for treating neuropathy
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ，インコーポレーテッド 金属塩及びその使用
EP4777094A1 (en) * 2023-09-13 2026-07-22 The Board of Trustees of the University of Illinois Compositions for use in a method of treating a motor neuron disease or condition associated with a spg11 pathogenic variant
CN117224516A (zh) * 2023-11-01 2023-12-15 上海市第六人民医院 激活lxr/rxr通路的试剂在制备治疗als的药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057865A2 (en) * 1999-03-25 2000-10-05 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
JP2004509161A (ja) * 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970006890B1 (ko) * 1987-10-20 1997-04-30 오스카 세이야꾸 가부시끼가이샤 페닐카르복시산 유도체 및 그 염
ATE236137T1 (de) * 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
KR20010031501A (ko) * 1997-10-31 2001-04-16 추후제출 5-알파 환원효소 활성을 조절하는 방법 및 조성물
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
WO2000055318A2 (en) * 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
US20040137423A1 (en) * 1999-03-15 2004-07-15 Hayden Michael R. Compositions and methods for modulating HDL cholesterol and triglyceride levels
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
US20060025393A1 (en) * 1999-04-30 2006-02-02 Shutsung Liao Steroid derivatives
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
AU1291901A (en) * 1999-09-01 2001-03-26 University Of British Columbia, The Compositions and methods for modulating hdl cholesterol and triglyceride levels
EP1239855A4 (en) * 1999-12-13 2004-04-21 Merck & Co Inc METHOD FOR PREVENTING AND TREATING ARTERIOSCLEROSIS
US20030086923A1 (en) * 1999-12-13 2003-05-08 Sparrow Carl P. Method for the prevention and/or treatment of atherosclerosis
WO2002062302A2 (en) * 2001-02-08 2002-08-15 The University Of Chicago Steroidal derivatives
JP4309661B2 (ja) * 2001-05-03 2009-08-05 ザ ユニバーシティー オブ シカゴ 肝臓ｘ受容体
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
AU2002304931A1 (en) * 2001-06-08 2002-12-23 University Of British Columbia Methods for treating disorders of the nervous and reproductive systems
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7998986B2 (en) * 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
AU2003226094A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
US7323494B2 (en) * 2002-03-27 2008-01-29 Smithkline Beecham Corporation Compounds and methods
US20050136421A1 (en) * 2003-12-23 2005-06-23 Hayden Michael R. Methods and reagents for modulating cholesterol levels

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000057865A2 (en) * 1999-03-25 2000-10-05 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
WO2000066611A1 (en) * 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
WO2001003705A1 (en) * 1999-07-08 2001-01-18 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
JP2004509161A (ja) * 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005521705A (ja) * 2002-03-27 2005-07-21 スミスクライン・ビーチャム・コーポレイション 化合物および方法

Also Published As

Publication number Publication date
US20050171084A1 (en) 2005-08-04
AU2003220521A1 (en) 2003-10-13
WO2003082198A3 (en) 2004-12-23
AU2003220521A8 (en) 2003-10-13
EP1511483A4 (en) 2009-03-18
WO2003082198A2 (en) 2003-10-09
EP1511483A2 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
US20050171084A1 (en) Methods of treatment with lxr modulators
US11130779B2 (en) PPAR agonists and methods of use thereof
US11420934B2 (en) PPAR agonists
JP5589037B2 (ja) 退行性脳疾患の予防用または治療用の薬学的組成物及びそのスクリーニング方法
JP6479913B2 (ja) ＩＲＥ−１αインヒビター
JP5685532B2 (ja) 新しい治療用作用物質
US20040034075A1 (en) Sphingosine kinase inhibitors
JP2010522735A (ja) 腫瘍成長阻害剤としてのテトラヒドロイソキノリン
JP5392776B2 (ja) 新規ベンゾフラン系誘導体を含む認知機能障害の治療及び予防用組成物とその使用
IL275387A (en) Agonists, compounds, pharmaceuticals and methods of use ppar,
JPH11335375A (ja) ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
EA020496B1 (ru) Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
KR101208760B1 (ko) 히스톤 탈아세틸화 효소의 억제를 위한 신남 화합물 및 이로부터의 유도체
BR112021009921A2 (pt) composição farmacêutica que compreende inibidores de histona desacetilase 6
JP2017536346A (ja) 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
JP2016185947A (ja) ＩＲＥ−１αインヒビター
KR20090075827A (ko) 인슐린 저항 또는 고혈당증에 관련된 대사성 질환용 피리딘 유도체
JP2005521705A (ja) 化合物および方法
US20070219245A1 (en) Method of use for substituted dipiperidine ccr2 antagonists
MX2014001526A (es) Inhibidores suaves novedosos de pde4.
CA2335293A1 (en) Inhibitors of transcription factor nf-.kappa.b
JP4550353B2 (ja) 造血器型プロスタグランジンｄ２合成酵素阻害剤
JP2007500158A (ja) Ｌｘｒアゴニストを用いる炎症性腸疾患の治療方法
US20060189693A1 (en) Methods of treatment with lxr agonists
JP2019522650A (ja) ４−（５−（４，７−ジメチルベンゾフラン−２−イル）−１，２，４−オキサジアゾール−３−イル）安息香酸の結晶形態及びそれらの調製方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090826

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090925

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091026

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100914

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20110125